Literature DB >> 28782606

Epigenetics in ovarian cancer.

Yanina Natanzon1, Ellen L Goode1, Julie M Cunningham2.   

Abstract

Ovarian cancer is a disease with a poor prognosis and little progress has been made to improve treatment. It is now recognized that there are several histotypes of ovarian cancer, each with distinct epidemiologic and genomic characteristics. Cancer therapy is moving beyond classical chemotherapy to include epigenetic approaches. Epigenetics is the dynamic regulation of gene expression by DNA methylation and histone post translational modification in response to environmental cues. Improvement in technology to study DNA methylation has enabled a more agnostic approach and, with larger samples sets, has begun to unravel how epigenetics contributes to the etiology, response to chemotherapy and prognosis in of ovarian cancer. Investigations into histone modifications in ovarian cancer are more nascent. Much more is needed to be done to fully realize the potential that epigenetics holds for ovarian cancer clinical care.
Copyright © 2017 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Chromatin; DNA methylation; Ovarian cancer

Mesh:

Year:  2017        PMID: 28782606      PMCID: PMC5976557          DOI: 10.1016/j.semcancer.2017.08.003

Source DB:  PubMed          Journal:  Semin Cancer Biol        ISSN: 1044-579X            Impact factor:   15.707


  135 in total

Review 1.  Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancer.

Authors:  Saverio Minucci; Pier Giuseppe Pelicci
Journal:  Nat Rev Cancer       Date:  2006-01       Impact factor: 60.716

2.  Promoter hypermethylation and BRCA1 inactivation in sporadic breast and ovarian tumors.

Authors:  M Esteller; J M Silva; G Dominguez; F Bonilla; X Matias-Guiu; E Lerma; E Bussaglia; J Prat; I C Harkes; E A Repasky; E Gabrielson; M Schutte; S B Baylin; J G Herman
Journal:  J Natl Cancer Inst       Date:  2000-04-05       Impact factor: 13.506

3.  High-throughput DNA hypermethylation profiling in different ovarian epithelial cancer subtypes using universal bead array.

Authors:  Man Soo Yoon; Dong Soo Suh; Kyung Un Choi; Mee Young Sol; Dong Hoon Shin; Won Young Park; Jung Hee Lee; Seong Muk Jeong; Woo Gyeong Kim; Na Ri Shin
Journal:  Oncol Rep       Date:  2010-10       Impact factor: 3.906

4.  A phase 1 and pharmacodynamic study of decitabine in combination with carboplatin in patients with recurrent, platinum-resistant, epithelial ovarian cancer.

Authors:  Fang Fang; Curt Balch; Jeanne Schilder; Timothy Breen; Shu Zhang; Changyu Shen; Lang Li; Carol Kulesavage; Anthony J Snyder; Kenneth P Nephew; Daniela E Matei
Journal:  Cancer       Date:  2010-09-01       Impact factor: 6.860

5.  Environmental and heritable factors in the causation of cancer--analyses of cohorts of twins from Sweden, Denmark, and Finland.

Authors:  P Lichtenstein; N V Holm; P K Verkasalo; A Iliadou; J Kaprio; M Koskenvuo; E Pukkala; A Skytthe; K Hemminki
Journal:  N Engl J Med       Date:  2000-07-13       Impact factor: 91.245

6.  Distinct DNA methylation profiles in ovarian serous neoplasms and their implications in ovarian carcinogenesis.

Authors:  Ie-Ming Shih; Li Chen; Chen C Wang; Jinghua Gu; Ben Davidson; Leslie Cope; Robert J Kurman; Jianhua Xuan; Tian-Li Wang
Journal:  Am J Obstet Gynecol       Date:  2010-10-20       Impact factor: 8.661

7.  Population pharmacokinetics and pharmacodynamics of doxorubicin and cyclophosphamide in breast cancer patients: a study by the EORTC-PAMM-NDDG.

Authors:  Markus Joerger; Alwin D R Huitema; Dick J Richel; Christian Dittrich; Nikolas Pavlidis; Evangelos Briasoulis; Jan B Vermorken; Elena Strocchi; Andrea Martoni; Roberto Sorio; Henk P Sleeboom; Miguel A Izquierdo; Duncan I Jodrell; Régine Féty; Ernst de Bruijn; Georg Hempel; Mats Karlsson; Brigitte Tranchand; Ad H G J Schrijvers; Chris Twelves; Jos H Beijnen; Jan H M Schellens
Journal:  Clin Pharmacokinet       Date:  2007       Impact factor: 6.447

8.  Hypermethylation of P15, P16, and E-cadherin genes in ovarian cancer.

Authors:  Said S Moselhy; Taha A Kumosani; I H Kamal; J A Jalal; Hassan S Abdul Jabaar; Ashraf Dalol
Journal:  Toxicol Ind Health       Date:  2013-04-09       Impact factor: 2.273

9.  A survival analysis comparing women with ovarian low-grade serous carcinoma to those with high-grade histology.

Authors:  Ming Chen; Ying Jin; Yalan Bi; Jie Yin; Yongxue Wang; Lingya Pan
Journal:  Onco Targets Ther       Date:  2014-10-16       Impact factor: 4.147

10.  A phase I trial of azacitidine and nanoparticle albumin bound paclitaxel in patients with advanced or metastatic solid tumors.

Authors:  Adam L Cohen; Abhijit Ray; Matthew Van Brocklin; David M Burnett; Randy C Bowen; Donna L Dyess; Thomas W Butler; Theresa Dumlao; Hung T Khong
Journal:  Oncotarget       Date:  2016-12-26
View more
  32 in total

1.  Decreased DHRS2 expression is associated with HDACi resistance and poor prognosis in ovarian cancer.

Authors:  Yingyan Han; Zhi Wang; Shujuan Sun; Zeyu Zhang; Jia Liu; Xin Jin; Peng Wu; Teng Ji; Wencheng Ding; Beibei Wang; Qinglei Gao
Journal:  Epigenetics       Date:  2019-09-03       Impact factor: 4.528

Review 2.  Epigenetic Attire in Ovarian Cancer: The Emperor's New Clothes.

Authors:  Daniela Matei; Kenneth P Nephew
Journal:  Cancer Res       Date:  2020-05-07       Impact factor: 12.701

3.  Activation of RIPK2-mediated NOD1 signaling promotes proliferation and invasion of ovarian cancer cells via NF-κB pathway.

Authors:  WenJuan Zhang; YanYan Wang
Journal:  Histochem Cell Biol       Date:  2021-11-26       Impact factor: 4.304

4.  The Expression and Role Analysis of Methylation-Regulated Differentially Expressed Gene UBE2C in Pan-Cancer, Especially for HGSOC.

Authors:  Jiajia Li; Yating Sun; Xiuling Zhi; Qin Li; Liangqing Yao; Mo Chen
Journal:  Cancers (Basel)       Date:  2022-06-25       Impact factor: 6.575

5.  Epigenetic Silencing of DAPK1and p16 INK4a Genes by CpG Island Hypermethylation in Epithelial Ovarian Cancer Patients.

Authors:  Mariyam Zuberi; Sagar Dholariya; Imran Khan; Rashid Mir; Sameer Guru; Musadiq Bhat; Mamta Sumi; Alpana Saxena
Journal:  Indian J Clin Biochem       Date:  2020-05-16

6.  LAMA3 DNA methylation and transcriptome changes associated with chemotherapy resistance in ovarian cancer.

Authors:  Li-Yuan Feng; Yong-Zhi Huang; Wei Zhang; Li Li
Journal:  J Ovarian Res       Date:  2021-05-15       Impact factor: 4.234

7.  A multi-level investigation of the genetic relationship between endometriosis and ovarian cancer histotypes.

Authors:  Sally Mortlock; Rosario I Corona; Pik Fang Kho; Paul Pharoah; Ji-Heui Seo; Matthew L Freedman; Simon A Gayther; Matthew T Siedhoff; Peter A W Rogers; Ronald Leuchter; Christine S Walsh; Ilana Cass; Beth Y Karlan; B J Rimel; Grant W Montgomery; Kate Lawrenson; Siddhartha P Kar
Journal:  Cell Rep Med       Date:  2022-03-15

Review 8.  Therapeutic Prospects of Polysaccharides for Ovarian Cancer.

Authors:  Kaili Wang; Mengcheng Cai; Shuai Sun; Wen Cheng; Dongxia Zhai; Zhexin Ni; Chaoqin Yu
Journal:  Front Nutr       Date:  2022-04-07

9.  Cross-linked hyaluronan gel inhibits the growth and metastasis of ovarian carcinoma.

Authors:  Ji Pang; Pengcheng Jiang; Ying Wang; Lu Jiang; Hai Qian; Yan Tao; Ruxia Shi; Jizong Gao; Yongchang Chen; Yan Wu
Journal:  J Ovarian Res       Date:  2018-03-06       Impact factor: 4.234

Review 10.  Are ovarian cancer stem cells the target for innovative immunotherapy?

Authors:  Liang Wang; Tianmin Xu; Manhua Cui
Journal:  Onco Targets Ther       Date:  2018-05-08       Impact factor: 4.147

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.